JP2023553253A5 - - Google Patents

Info

Publication number
JP2023553253A5
JP2023553253A5 JP2023526173A JP2023526173A JP2023553253A5 JP 2023553253 A5 JP2023553253 A5 JP 2023553253A5 JP 2023526173 A JP2023526173 A JP 2023526173A JP 2023526173 A JP2023526173 A JP 2023526173A JP 2023553253 A5 JP2023553253 A5 JP 2023553253A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
period
composition according
day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057123 external-priority patent/WO2022094133A1/en
Publication of JP2023553253A publication Critical patent/JP2023553253A/ja
Publication of JP2023553253A5 publication Critical patent/JP2023553253A5/ja
Pending legal-status Critical Current

Links

JP2023526173A 2020-10-28 2021-10-28 重水素化jak阻害剤による脱毛障害の治療のためのレジメン Pending JP2023553253A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US63/106,790 2020-10-28
US202163155637P 2021-03-02 2021-03-02
US63/155,637 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
JP2023553253A JP2023553253A (ja) 2023-12-21
JP2023553253A5 true JP2023553253A5 (cg-RX-API-DMAC7.html) 2024-11-01

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526173A Pending JP2023553253A (ja) 2020-10-28 2021-10-28 重水素化jak阻害剤による脱毛障害の治療のためのレジメン

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2024133474A5 (cg-RX-API-DMAC7.html)
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2024531188A5 (cg-RX-API-DMAC7.html)
JP2019516684A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2019503365A5 (cg-RX-API-DMAC7.html)
JP2021525729A5 (cg-RX-API-DMAC7.html)
JP2019517587A5 (cg-RX-API-DMAC7.html)
JP2020534270A5 (cg-RX-API-DMAC7.html)
HRP20241345T1 (hr) Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2024515829A5 (cg-RX-API-DMAC7.html)
JP2023116697A5 (cg-RX-API-DMAC7.html)
JP2021502392A5 (cg-RX-API-DMAC7.html)
JPWO2023054732A5 (cg-RX-API-DMAC7.html)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP2022514537A5 (cg-RX-API-DMAC7.html)
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP2023531675A5 (cg-RX-API-DMAC7.html)
JP2023549849A5 (cg-RX-API-DMAC7.html)